bBHC CO.,LTD
- Biotech or pharma, therapeutic R&D
bBHC has developed KH cells (KHCs), a novel cell type with trilineage differentiation potential and no observable tumorigenicity, obtained by non-genetic reprogramming of human umbilical cord-derived mesenchymal stem cells (UC MSCs) using natural compounds.
KHCs exhibit increased expression of anti-aging and tumor suppressor genes, transcription factors critical for blastocyst formation, and cytotoxic T-cell markers, while significantly inhibiting cancer cell survival and invasion. They also demonstrate minimal immunogenicity and no signs of teratoma formation or malignant transformation.
Monday, June 16 at 1 : 45 PM in Room 153C. We have presentation.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}